Last updated: February 12, 2026
Overview
NDC 00054-3721 records the drug Lomitapide, a lipid-lowering agent approved for managing Homozygous Familial Hypercholesterolemia (HoFH). As of 2023, Lomitapide remains a niche product with limited market penetration compared to statins. Its high cost, specialized indication, and evolving competitive landscape influence current market dynamics and future pricing.
Market Landscape
Indication Scope
- Approved for very rare genetic disorder Homozygous Familial Hypercholesterolemia.
- Population size estimated at fewer than 20,000 U.S. patients.
- Typically prescribed in specialty pharmacies; high-cost, low-volume market.
Competitive Environment
- Direct competitors include Mipomersen (withdrawn), Lomitapide (brand name: Juxtapid), and emerging gene therapies targeting LDL-C reduction.
- Statins and PCSK9 inhibitors cover broader hypercholesterolemia populations, but are less targeted for HoFH.
- Currently, no generic versions of Lomitapide exist due to patent protections.
Market Size and Penetration
- The global HoFH patient population is approximately 3,000 to 5,000.
- U.S. prevalence estimated at 1 in 1 million, translating to roughly 150-200 patients.
- Only a subset receive Lomitapide; estimates suggest fewer than 50 annual prescriptions.
Pricing Trends
- The current wholesale acquisition cost (WAC) is approximately $385,000 annually per patient (per GoodRx prices and pharmacy negotiations).
- Commercial insurance reimbursement averages between $330,000 and $380,000 annually.
- No generic competition affects price stability over the near term.
Historical Price Trends
| Year |
Approximate Price (per year) |
Notes |
| 2013 |
$385,000 |
Initial approval, high-cost niche drug |
| 2018 |
Stable |
No significant price reduction |
| 2022 |
Slight stabilization |
Moderate coverage expansion, price held |
Price Projections (Next 5 Years)
| Year |
Estimated Price Range |
Rationale |
| 2023 |
$375,000–$385,000 |
Stable pricing, with slight fluctuations due to market factors |
| 2024 |
$360,000–$385,000 |
Price pressure from payers, but limited competition keeps prices stable |
| 2025 |
$355,000–$380,000 |
Slight decrease expected, but high-cost niche limits volatility |
| 2026 |
$350,000–$375,000 |
Continued stabilization; no generic rival in sight |
| 2027 |
$340,000–$370,000 |
Small declines as insurance negotiations tighten |
Factors Influencing Price Trends
- Patent protection: Patent expiry is unlikely within the forecast window, maintaining a monopoly.
- Reimbursement policies: Payers prioritize cost containment; high list prices can limit patient access and impact net prices.
- Market expansion: Unlikely, given the extremely small target population.
- Regulatory developments: Potential approval of gene therapy could impact raw demand or shift pricing strategies.
Implications for Stakeholders
- Pharmaceutical companies: Price stability favors sustained high margins but restricts volume growth.
- Payers: Strong negotiating position due to limited alternatives and small patient population.
- Patients: High out-of-pocket costs under commercial plans, unless subsidized or covered by assistance programs.
Key Takeaways
- NDC 00054-3721 (Lomitapide) remains a high-cost, niche medication with a stable price due to lack of competition.
- The annual price hovers around $350,000–$385,000, with minimal downward pressure.
- Market size remains small and largely limited to specialized centers.
- Future price reductions are unlikely barring significant patent or regulatory changes.
- The evolving pipeline, including gene therapies, could alter long-term dynamics but is not imminent.
FAQs
1. What is the primary driver of Lomitapide's high price?
Limited patient population, no generic competition, and the drug's status as an orphan disease treatment sustain its high price.
2. Are there any upcoming patent expirations or biosimilar options?
As of 2023, Lomitapide's patents remain in force, preventing biosimilar or generic competition.
3. How do insurance policies typically reimburse for Lomitapide?
Reimbursement usually covers a significant portion of the cost, but out-of-pocket expenses can still be substantial for patients.
4. Could new therapies reduce Lomitapide’s market share?
Yes. Advances in gene therapy and other novel treatments could reduce demand, but these are likely years away from widespread adoption.
5. What regulatory factors could influence the drug’s pricing?
Regulatory approval of alternative treatments or policy changes targeting high orphan drug prices could impact future pricing.
Sources
- FDA Drug Database. Lomitapide [online].
- IQVIA. U.S. Prescription Data. 2023.
- GoodRx. Drug Prices. 2023.
- Orphanet. Homozygous Familial Hypercholesterolemia (HoFH). 2023.
- EvaluatePharma. Orphan Drug Market Analysis. 2023.
[1] FDA Database
[2] IQVIA Prescription Data 2023
[3] GoodRx Price Listings 2023
[4] Orphanet Data, 2023
[5] EvaluatePharma, 2023
